

Name of the Issue: Akums Drugs and Pharmaceuticals Limited			
1	Type of Issue	Initial Public Offer	
2	Issue Size (Rs. Mn)	18567.37*	
*Source: Prospectus dated August 1, 2024			
3	Grade of issue along with name of the rating agency		
	Name	NA	
	Grade	NA	
4	Subscription Level (Number of times)	64.64*	
* excluding Anchor Investor Portion and after removing multiple and duplicate bids			
Source: Minutes for basis of allotment dated August 2, 2024			
5	QIB Holding (as a %age of Outstanding Capital) as disclosed to the stock exchanges		
	Particulars	%	
	(i) On Allotment **	12.92	
	(ii) at the end of the 1st Quarter immediately after the listing of the issue (September 30, 2024)	14.86	
	(iii) at the end of 1st FY (March 31, 2025)	13.17	
	(iv) at the end of 2nd FY (March 31, 2026)	15.72	
	(v) at the end of 3rd FY (March 31, 2027) *	Not Available	
**Basis of Allotment (excluding pre-issue QIB holding)			
* QIB Holding not disclosed as reporting for relevant period has not been completed.			
6	Financials of the issuer		in Millions
	Parameters	1st FY (March 31,2025)	2nd FY (March 31,2026)
	Income from operations	41,181.58	43,590
	Net Profit/(Loss) for the period	3,821.10	2,564
	Paid-up equity share capital	306.21	306
	Reserves excluding revaluation reserves	30,163.93	32,82,727
			Not Available
* Financials not available as reporting for the relevant years has not been completed.			
7	Trading Status		
The equity shares of Mankind Pharma Limited are listed on both the BSE Limited ("BSE") and the National Stock Exchange of India Limited ("NSE") (and together with BSE the "Stock Exchanges")			
The equity shares have not been suspended or delisted.			
	Particulars	Status	
	(i) at the end of 1st FY (March 31, 2025)	Frequently	
	(ii) at the end of 2nd FY (March 31, 2026)	Frequently	
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	
* Trading status not disclosed as the relevant fiscal years have not been completed.			
8	Change in Directors of Issuer from the disclosures in the offer document		
	Particulars	Name of Director	Appointed / Resigned
	(i) at the end of 1st FY (March 31, 2025)	Mr. Nand Lal Kalra	Cessation due to attaining age
	(ii) at the end of 2nd FY (March 31, 2026)	Not Available	Not Available
	(iii) at the end of 3rd FY (March 31, 2027)*	Not Available	Not Available
* Changes in Directors of Issuer not updated as the relevant financial years have not been completed			

9 Status of implementation of project/ commencement of commercial production

(i) as disclosed in the offer document	Not applicable
(ii) Actual implementation	Not applicable
(iii) Reasons for delay in implementation, if any	Not applicable

10 Status of utilization of issue proceeds

(i) as disclosed in the offer document

Particulars	Amount proposed to be financed from Net Proceeds	Estimated Utilisation of Net Proceeds in Fiscal 2025	Estimated Utilisation of Net Proceeds in Fiscal 2026 and beyond
Repayment/ prepayment of indebtedness of the Company	1599.10	1599.10	0.00
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2270.90	-	2270.90
Funding incremental working capital requirements of our Company	550.00	-	550.00
Pursuing inorganic growth initiatives through acquisitions	278.70	-	278.70
General corporate purposes	1675.00	-	1675.00
Total Proceeds	6373.70	1599.10	4774.60

(ii) Actual implementation

Particulars	Amount proposed to be financed from Net Proceeds	Actual Utilisation of Net Proceeds	Unutilised Net Proceeds
Repayment/ prepayment of indebtedness of the Company	1599.10	1599.10	0.00
Repayment/ prepayment of indebtedness of its Subsidiaries namely, Maxcure Nutravedics Limited and Pure and Cure Healthcare Private Limited	2270.90	2270.90	0.00
Funding incremental working capital requirements of our Company	550.00	550.00	0.00
Pursuing inorganic growth initiatives through acquisitions	301.80	278.70	23.10
General corporate purposes	1700.00	1675.00	25.00
Total Proceeds	6421.80	6373.70	48.10

(iii) Reasons for delay in implementation, if any Not applicable

11 Comments of monitoring agency, if applicable

(i) Comments on use of funds

(ii) Comments on deviations, if any, in the use of proceeds of the Issue from the objects stated in the Offer document

(iii) Any other reservations expressed by the monitoring agency about the end use of funds

During the quarter ended March 31, 2026, the amount proposed towards the object for Inorganic expansion and general corporate purpose has been revised as per board resolution dated February 13, 2026
Nil
Nil

12 Pricing Data

Designated Stock Exchange NSE
Issue Price (Rs.) 679.00
Listing Date 6-Aug-24

Price parameters	At close of listing day August 06, 2024	Close of 30th calendar day from listing day	Close of 90th calendar day from listing day	As at the end of the 1st FY after the listing of the issue (31st March, 2025)		
				Closing price	High	Low
Market Price	679.00	855.25	845.3	471.1	480.5	466.0
Nifty 50*	23,992.55	25,418.55	23,995.35	23,165.70	23,565.15	23,136.40

Price parameters	As at the end of the 2nd FY after the listing of the issue (31st March, 2026)			As at the end of the 3rd FY after the listing of the issue (31st March, 2027) ⁽¹⁾		
	Closing price	High	Low	Closing price	High	Low
Market Price	466.1	594.0	414.1	Not Available	Not Available	Not Available
Nifty 50*	22,331.4	26,328.6	22,161.6	Not Available	Not Available	Not Available

* Being index of NSE, the designated stock exchange

(1) The pricing data is not disclosed as the relevant fiscal years have not been completed

13 Basis for Issue Price

Accounting ratio	Face Value per share (Rs.)	As disclosed in offer document*	At the end of 1st FY (March 31,2025)	At the end of 1st FY (March 31,2026)	At the end of 1st FY (March 31,2027)**
EPS (Diluted)	Company				
	Consolidated	2	-0.28	22.60	16.67
	Peer Group:				Not Available
	Divi's Laboratories	2	60.27	83.20	96.75
	Suven Pharma (Now Cohance Lifesciences)	1	11.8	10.45	4.68
	Gland Pharma	1	46.89	42.40	62.28
	Torrent Pharma	5	48.94	56.47	63.92
	Alkem Laboratories	2	150.19	181.11	192.51
	Eris Lifesciences	1	28.79	25.81	45.26
	JB Chemicals	1	34.85	41.56	44.45
	Mankind Pharma	1	47.68	49.08	46.28
	Innova Captab	10	18.66	22.41	24.63
	Industry Avg		49.79	56.94	64.53
P/E	Company				
	Consolidated	2	NA	20.84	27.96
	Peer Group:				Not Available
	Divi's Laboratories	2	74.99	66.69	61.35
	Suven Pharma (Now Cohance Lifesciences)	1	69.54	102.82	64.41
	Gland Pharma	1	42.45	36.68	27.23
	Torrent Pharma	5	60.2	56.34	66.02
	Alkem Laboratories	2	34.18	26.69	27.53
	Eris Lifesciences	1	34.95	53.89	28.66
	JB Chemicals	1	51.38	37.30	46.44
	Mankind Pharma	1	44.65	50.06	43.34
	Innova Captab	10	29.91	39.76	33.97
	Industry Avg		49.14	52.25	44.33
RoNW	Company				
	Consolidated	2	-0.57%	11.28%	12.54%
	Peer Group:				Not Available
	Divi's Laboratories	2	11.79%	14.83%	15.32%
	Suven Pharma (Now Cohance Lifesciences)	1	14.64%	15.61%	3.84%
	Gland Pharma	1	8.85%	7.63%	9.92%
	Torrent Pharma	5	24.15%	25.17%	25.49%
	Alkem Laboratories	2	17.41%	18.48%	17.01%
	Eris Lifesciences	1	15.16%	11.45%	16.36%
	JB Chemicals	1	18.90%	19.21%	17.17%
	Mankind Pharma	1	20.43%	14.03%	11.89%
	Innova Captab	10	11.35%	13.37%	12.92%
	Industry Avg		15.85%	15.53%	14.44%
NAV per share	Company				
	Consolidated	2	49.59	193.59	199.01
	Peer Group:				Not Available
	Divi's Laboratories	2	511.21	561.08	632.49
	Suven Pharma (Now Cohance Lifesciences)	1	80.56	44.35	102.23
	Gland Pharma	1	529.65	555.41	628.67
	Torrent Pharma	5	202.57	224.29	247.86
	Alkem Laboratories	2	862.46	1,002.37	1,156.01
	Eris Lifesciences	1	190.12	240.28	281.78
	JB Chemicals	1	188.37	220.54	257.33
	Mankind Pharma	1	233.73	347.39	394.87
	Innova Captab	10	145.2	167.66	190.61
	Industry Avg		327.10	373.71	432.43

Notes

* Sourced from Prospectus dated August 01, 2024.

**Not available as the relevant fiscal years have not been completed / information not disclosed

^ Price as on May 2026

14 Any other material information

Particulars	Date	Remarks
Not Applicable		

Source: Stock Exchange websites i.e. www.bseindia.com and www.nseindia.com